FINELLI, CARLO
FINELLI, CARLO
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine
2018 Visani, G; Loscocco, F; Ruzzo, A; Galimberti, S; Graziano, F; Voso, M T; Giacomini, E; Finelli, C; Ciabatti, E; Fabiani, E; Barulli, S; Volpe, A; Magro, D; Piccaluga, P; Fuligni, F; Vignetti, M; Fazi, P; Piciocchi, A; Gabucci, E; Rocchi, M; Magnani, M; Isidori, A
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna
2017 Follo, M.Y.; Pellagatti, A.; Armstrong, R.N.; Mongiorgi, S.; Astolfi, A.; Indio, V.; Ratti, S.; Clissa, C.; Barraco, M.; Parisi, S.; Manzoli, L.; Pession, A.; Cocco, L.; Boultwood, J.; Finelli, C.
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
2016 Finelli, Carlo; Follo, Matilde Y; Stanzani, Marta; Parisi, Sarah; Clissa, Cristina; Mongiorgi, Sara; Barraco, Marilena; Cocco, Lucio
Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment
2016 Stefano Ratti, Sara Mongiorgi, Marta Stanzani, Carlo Finelli, Lucio Ildebrando Cocco, Lucia Manzoli, Anna Maria Billi, Irene Faenza, Giulia Ramazzotti, Roberta Fiume, Matilde Yung Follo
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes
2016 Mongiorgi, Sara; Finelli, Carlo; Yang, Yong Ryoul; Clissa, Cristina; Mccubrey, James A.; Billi, Anna Maria; Manzoli, Lucia; Suh, Pann-Ghill; Cocco, Lucio; Follo, Matilde Y
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes
2015 Cocco, Lucio; Finelli, Carlo; Mongiorgi, Sara; Clissa, Cristina; Russo, Domenico; Bosi, Costanza; Quaranta, Marilisa; Malagola, Michele; Parisi, Sarah; Stanzani, Marta; Ramazzotti, Giulia; Mariani, Giulia A.; Billi, Anna Maria; Manzoli, Lucia; Follo, Matilde Y.
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"]
2014 Martinelli, Giovanni; Sartor, Chiara; Papayannidis, Cristina; Iacobucci, Ilaria; Paolini, Stefania; Clissa, Cristina; Ottaviani, Emanuela; Finelli, Carlo
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES
2014 Follo, My; Mongiorgi, S; Clissa, C; Stanzani, M; Poli, A; Lonetti, A; Cappellini, A; Manzoli, L; Cocco L, 1; Finelli, C
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML)
2014 Cristina Papayannidis, Stefania Paolini, Emanuela Ottaviani, Federica Salmi, Barbara Lama, Antonio Curti, Ilaria Iacobucci, Sarah Parisi, Cristina Clissa, Pier Paolo Piccaluga, Daniela Cilloni, Giuseppe Saglio, Anna Candoni, Fortunato Morabito, Carlo Finelli, Nicola Vianelli, Mitch Raponi, Massimo Serra, Michele Baccarani, Giovanni Martinelli
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy
2014 Manzoli L; Mongiorgi S; Clissa C; Finelli C; Billi AM; Poli A; Quaranta M; Cocco L; Follo MY
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS
2013 Clissa C;Finelli C;Follo MY; Stanzani M; Curti A; Paolini S; Papayannidis C; Mongiorgi S; Parisi S; Abbenante MC; Bosi C; Manzoli L; Martinelli G; Cocco L; Cavo M
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide
2013 M.Y. Follo; S. Mongiorgi; C. Clissa; M. Stoyanova; S. Paolini; M. Quaranta; G. Martinelli; L. Manzoli; C. Cocco; C. Finelli
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE
2013 Follo MY; Clissa C; Mongiorgi S; Stoyanova M; Paolini S; Quaranta M; Stanzani M; Martinelli G; Manzoli L; Cocco L; Finelli C
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)
2013 Matilde Y Follo; Carlo Finelli; Cristina Clissa; Sara Mongiorgi; Carmen Baldazzi; Marta Stanzani; Michele Baccarani; Lucio Cocco
Long-lasting hematologic response to azacitidine in myelodysplastic syndromes: Multicenter retrospective study of 36 patients
2013 C. Finelli; C. Clissa; M.T. Voso; M.A. Aloe Spiriti; M. Breccia; G. Gaidano; M. Crugnola; M.B. Giannini; A. Poloni; C. Bosi; V. Naso; M.Y. Follo; G. Martinelli; M. Cavo
Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS
2013 Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
PI-PLCBETA1 GENE METHYLATION AND EXPRESSION AS A RELIABLE AND DYNAMIC MARKER OF CLINICAL RESPONSE TO 5-AZACYTIDINE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES
2013 Follo MY; Malagola M; Filì C; Finelli C; Iacobucci I; Martinelli G; Cattina F; Clissa C;Candoni A; Fanin R; Gobbi M; Bocchia M; Defina M; Spedini P; Skert C; Manzoli L; Cocco L; Russo D
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes
2013 Filì C; Malagola M; Follo MY; Finelli C; Iacobucci I; Martinelli G; Cattina F; Clissa C; Candoni A; Fanin R; Gobbi M; Bocchia M; Defina M; Spedini P; Skert C; Manzoli L; Cocco L; Russo D.
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients
2012 Follo M.Y.; Mongiorgi S.; Clissa C.; Paolini S.; Martinelli G.; Martelli A.M.; Fioravanti G.; Manzoli L.; Finelli C.; Cocco L.
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients
2012 Carlo Finelli; Cristina Clissa; Maria Teresa Voso; Maria Antonietta Aloe Spiriti; Massimo Breccia; Gianluca Gaidano; Monica Crugnola; Maria Benedetta Giannini; Costanza Bosi; Virginia Naso; Matilde Y Follo; Sara Mongiorgi; Giovanni Martinelli; Lucio Cocco; Michele Baccarani
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine | Visani, G; Loscocco, F; Ruzzo, A; Galimberti, S; Graziano, F; Voso, M T; Giacomini, E; Finelli, C...; Ciabatti, E; Fabiani, E; Barulli, S; Volpe, A; Magro, D; Piccaluga, P; Fuligni, F; Vignetti, M; Fazi, P; Piciocchi, A; Gabucci, E; Rocchi, M; Magnani, M; Isidori, A | 2018-01-01 | PHARMACOGENOMICS JOURNAL | - | 1.01 Articolo in rivista | - |
| Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna | Follo, M.Y.; Pellagatti, A.; Armstrong, R.N.; Mongiorgi, S.; Astolfi, A.; Indio, V.; Ratti, S.; C...lissa, C.; Barraco, M.; Parisi, S.; Manzoli, L.; Pession, A.; Cocco, L.; Boultwood, J.; Finelli, C. | 2017-01-01 | LEUKEMIA RESEARCH | - | 4.01 Contributo in Atti di convegno | - |
| Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes | Finelli, Carlo; Follo, Matilde Y; Stanzani, Marta; Parisi, Sarah; Clissa, Cristina; Mongiorgi, Sa...ra; Barraco, Marilena; Cocco, Lucio | 2016-01-01 | CURRENT PHARMACEUTICAL DESIGN | - | 1.01 Articolo in rivista | - |
| Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment | Stefano Ratti, Sara Mongiorgi, Marta Stanzani, Carlo Finelli, Lucio Ildebrando Cocco, Lucia Manzo...li, Anna Maria Billi, Irene Faenza, Giulia Ramazzotti, Roberta Fiume, Matilde Yung Follo | 2016-01-01 | - | - | 4.01 Contributo in Atti di convegno | - |
| Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes | Mongiorgi, Sara; Finelli, Carlo; Yang, Yong Ryoul; Clissa, Cristina; Mccubrey, James A.; Billi, A...nna Maria; Manzoli, Lucia; Suh, Pann-Ghill; Cocco, Lucio; Follo, Matilde Y | 2016-01-01 | EXPERT OPINION ON THERAPEUTIC TARGETS | - | 1.01 Articolo in rivista | - |
| An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes | Cocco, Lucio; Finelli, Carlo; Mongiorgi, Sara; Clissa, Cristina; Russo, Domenico; Bosi, Costanza;... Quaranta, Marilisa; Malagola, Michele; Parisi, Sarah; Stanzani, Marta; Ramazzotti, Giulia; Mariani, Giulia A.; Billi, Anna Maria; Manzoli, Lucia; Follo, Matilde Y. | 2015-01-01 | JOURNAL OF LEUKOCYTE BIOLOGY | - | 1.01 Articolo in rivista | - |
| [Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] | Martinelli, Giovanni; Sartor, Chiara; Papayannidis, Cristina; Iacobucci, Ilaria; Paolini, Stefani...a; Clissa, Cristina; Ottaviani, Emanuela; Finelli, Carlo | 2014-01-01 | RECENTI PROGRESSI IN MEDICINA | - | 1.01 Articolo in rivista | - |
| DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES | Follo, My; Mongiorgi, S; Clissa, C; Stanzani, M; Poli, A; Lonetti, A; Cappellini, A; Manzoli, L; ...Cocco L, 1; Finelli, C | 2014-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) | Cristina Papayannidis, Stefania Paolini, Emanuela Ottaviani, Federica Salmi, Barbara Lama, Antoni...o Curti, Ilaria Iacobucci, Sarah Parisi, Cristina Clissa, Pier Paolo Piccaluga, Daniela Cilloni, Giuseppe Saglio, Anna Candoni, Fortunato Morabito, Carlo Finelli, Nicola Vianelli, Mitch Raponi, Massimo Serra, Michele Baccarani, Giovanni Martinelli | 2014-01-01 | CANCER RESEARCH | - | 1.06 Abstract in rivista | - |
| Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy | Manzoli L; Mongiorgi S; Clissa C; Finelli C; Billi AM; Poli A; Quaranta M; Cocco L; Follo MY | 2014-01-01 | MINI-REVIEWS IN MEDICINAL CHEMISTRY | - | 1.01 Articolo in rivista | - |
| AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS |
Clissa C;Finelli C;Follo MY; Stanzani M; Curti A; Paolini S; Papayannidis C; Mongiorgi S; Parisi ...S; Abbenante MC; Bosi C; Manzoli L; Martinelli G; Cocco L; Cavo M |
2013-01-01 | HAEMATOLOGICA | - | 4.01 Contributo in Atti di convegno | - |
| Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide | M.Y. Follo; S. Mongiorgi; C. Clissa; M. Stoyanova; S. Paolini; M. Quaranta; G. Martinelli; L. Man...zoli; C. Cocco; C. Finelli | 2013-01-01 | LEUKEMIA RESEARCH | - | 4.01 Contributo in Atti di convegno | - |
| CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE |
Follo MY; Clissa C; Mongiorgi S; Stoyanova M; Paolini S; Quaranta M; Stanzani M; Martinelli G; Ma...nzoli L; Cocco L; Finelli C |
2013-01-01 | HAEMATOLOGICA | - | 4.01 Contributo in Atti di convegno | - |
| Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) | Matilde Y Follo; Carlo Finelli; Cristina Clissa; Sara Mongiorgi; Carmen Baldazzi; Marta Stanzani;... Michele Baccarani; Lucio Cocco | 2013-01-01 | BLOOD | - | 4.01 Contributo in Atti di convegno | - |
| Long-lasting hematologic response to azacitidine in myelodysplastic syndromes: Multicenter retrospective study of 36 patients | C. Finelli; C. Clissa; M.T. Voso; M.A. Aloe Spiriti; M. Breccia; G. Gaidano; M. Crugnola; M.B. Gi...annini; A. Poloni; C. Bosi; V. Naso; M.Y. Follo; G. Martinelli; M. Cavo | 2013-01-01 | LEUKEMIA RESEARCH | ELSEVIER | 4.01 Contributo in Atti di convegno | - |
| Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS | Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finell...i C; Manzoli FA; Cocco L | 2013-01-01 | ADVANCES IN BIOLOGICAL REGULATION | - | 1.01 Articolo in rivista | - |
| PI-PLCBETA1 GENE METHYLATION AND EXPRESSION AS A RELIABLE AND DYNAMIC MARKER OF CLINICAL RESPONSE TO 5-AZACYTIDINE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROMES |
Follo MY; Malagola M; Filì C; Finelli C; Iacobucci I; Martinelli G; Cattina F; Clissa C;Candoni A...; Fanin R; Gobbi M; Bocchia M; Defina M; Spedini P; Skert C; Manzoli L; Cocco L; Russo D |
2013-01-01 | HAEMATOLOGICA | - | 4.01 Contributo in Atti di convegno | - |
| Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes | Filì C; Malagola M; Follo MY; Finelli C; Iacobucci I; Martinelli G; Cattina F; Clissa C; Candoni ...A; Fanin R; Gobbi M; Bocchia M; Defina M; Spedini P; Skert C; Manzoli L; Cocco L; Russo D. | 2013-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients | Follo M.Y.; Mongiorgi S.; Clissa C.; Paolini S.; Martinelli G.; Martelli A.M.; Fioravanti G.; Man...zoli L.; Finelli C.; Cocco L. | 2012-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients | Carlo Finelli; Cristina Clissa; Maria Teresa Voso; Maria Antonietta Aloe Spiriti; Massimo Breccia...; Gianluca Gaidano; Monica Crugnola; Maria Benedetta Giannini; Costanza Bosi; Virginia Naso; Matilde Y Follo; Sara Mongiorgi; Giovanni Martinelli; Lucio Cocco; Michele Baccarani | 2012-01-01 | BLOOD | - | 4.02 Riassunto (Abstract) | - |